Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma
UID: 10534
- Description
- This dataset contains data on the tumor microenvironment from the whole bone marrow of 436 patients who were diagnosed with multiple myeloma and enrolled in the interventional Total Therapy trial series conducted by the University of Arkansas for Medical Sciences. 266 male and 170 female patients were enrolled between February 25, 2004 and January 11, 2014 and completed 25 to 5,241 days of follow-up with a mean of 2,628 days. In the Total Therapy trials, patients received personalized treatment with a combination of thalidomide, dexamethasone, and autologous bone marrow transplant as determined by tumor gene expression and cytogenetics. Samples were drawn at prior to the initiation of treatment as well as post-induction, post-transplantation, post-consolidation, or post-maintenance. A total of 1,424 samples of whole bone marrow and CD138+-selected plasma cell RNA sequences are available in the NCBI Gene Expression Omnibus (GEO) repository.
- Timeframe
- 2004 - 2019
- Geographic Coverage
-
Arkansas
- Local Expert
Homo sapiens
Subject Domain
Population Age
Keywords
Adult (19 years - 64 years)
Senior (65 years - 79 years)
Access
- Restrictions
-
Free to All
- Instructions
- Samples have been shared in the NCBI Gene Expression Omnibus (GEO) repository. Clinical information and metadata, including sample collection dates and multiple myeloma risk scores, are available in the supplemental files submitted with the associated publication.
Interventional
70-gene Prognostic Risk Score (GEP-70)
International Staging System (ISS) for Multiple Myeloma
- Other Resources
-
ClinicalTrials.gov
NCT00081939
ClinicalTrials.govNCT00572169
ClinicalTrials.govNCT00734877
ClinicalTrials.govNCT00869232
ClinicalTrials.govNCT02128230
Do you have or know of a dataset that should be added to the catalog? Let us know!